Medicinal Chemistry Research最新文献

{"title":"C(sp2)-Thio- and amino-methylated indole derivatives: one-pot synthesis, evaluation of cytotoxic and anti-inflammatory activity","authors":"V. R. Akhmetova,&nbsp;D. V. Leont’ev,&nbsp;N. S. Akhmadiev,&nbsp;V. N. Perfilova,&nbsp;V. S. Sirotenko,&nbsp;E. A. Paramonov,&nbsp;I. I. Prokofiev,&nbsp;M. A. Sagalaev,&nbsp;V. R. Khairullina,&nbsp;D. V. Ishmetova,&nbsp;Yu. V. Vakhitova","doi":"10.1007/s00044-026-03582-x","DOIUrl":"10.1007/s00044-026-03582-x","url":null,"abstract":"<div><p>Tricyclic 1-(3,4,5,6-tetrahydro-1<i>H</i>-[1,4,6]-thiadiazocino[4,3-a]-indol-12-yl)methanamides were synthesized as pyridine complexes using <i>one-pot</i>, four-component amino- and thiomethylation reactions of 1<i>Н</i>-indole with formaldehyde, secondary amines, and 1,2-aminothiol. C(sp²)-Thio- and/or <i>N</i>-aminomethylated indole derivatives were selectively obtained by three-component reaction of 1<i>H</i>-indole, 1<i>H</i>-indol-3-ylacetic acid (heteroauxin), or 3-dimethylamiomethyl-1<i>H</i>-indole (gramine) with formaldehyde and sulfur-containing amine. According to cytotoxicity assays in vitro, these products had favorable safety profiles. In an in vivo model of experimental osteoarthritis, 12-((dimethylamino)methyl)-3,4,5,6-tetrahydro-1<i>H</i>-[1,4,6]-thiadiazocino-[4,3-a]-indole-4-acetate pyridine solvate showed anti-inflammatory activity comparable with that of diclofenac. Furthermore, a molecular docking investigation was conducted to gain insight into the binding mode of the most promising compounds via the active sites of COX-1 (PDB ID: 3n8x) and COX-2 (PDB ID: 1pxx).</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"35 7","pages":"1330 - 1340"},"PeriodicalIF":3.5,"publicationDate":"2026-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148434532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacodynamic material basis investigations of the crude and processed Radix et Rhizoma Rhei by the immobilized β2-adrenoceptor chromatography","authors":"Guangyao Shen,&nbsp;Wen Yang,&nbsp;Yue Zhang,&nbsp;Qian Liu,&nbsp;Zihu Wang,&nbsp;Jia Wang,&nbsp;Minfeng Fang","doi":"10.1007/s00044-026-03580-z","DOIUrl":"10.1007/s00044-026-03580-z","url":null,"abstract":"<div><p>Radix et Rhizoma Rhei (DaHuang, DH), subjected to different processing procedures, always result in different therapeutic effects because the interactions of the compounds co-occur. Herein, a chromatographic method was established using immobilized β₂-adrenoceptor (β2-AR) as the stationary phase to separate bioactive compounds in crude and processed DH. The approaches involved in the expression of β₂-AR in the <i>Escherichia coli</i> system, the immobilization of the receptor onto the surface of the macro-porous silica gel by a one-step site-specific covalent method, parallel screening of the bioactive compounds in crude- and processed- DH extract by the immobilized β₂-AR column, identification of the bioactive compounds by mass spectrometry, evaluation of the binding interaction of the compound by injection amount-dependent method, and the potential binding mechanism of the interaction between the retained compound by molecular docking. Five compounds were identified as the bioactive compounds that specifically bind to the immobilized β₂-AR column in crude-DH, while three of them were from processed-DH. The association constants of the compounds to the receptor were calculated as (5.78 ± 0.25) ×10⁵ M^− 1 for chrysophanol-8-O-β-glucoside, (0.70 ± 0.02) ×10⁵ M^− 1 for emodin-8-O-glucoside, (12.72 ± 1.83)×10⁵ M^− 1 for aloe emodin, (1.34 ± 0.07)×10⁵ M^− 1 for emodin, and (2.96 ± 0.17)×10⁵ M^− 1 for physcion, respectively. These results, taken together, not only confirmed the feasibility of the immobilized receptor chromatography in revealing the pharmacodynamic material basis of the crude and processed drug, but also provided an alternative for illuminating the underlying mechanism of the pharmacological activities of the processed drug.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"35 6","pages":"1222 - 1234"},"PeriodicalIF":3.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148305946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design, Synthesis and Antitumor Activity Evaluation in Vitro of Novel 1,6-Naphthyridine Derivatives","authors":"Xiao-Jie Si,&nbsp;Xin-Yi Ma,&nbsp;Su-Lin Zhang,&nbsp;Ming-Yue Zheng,&nbsp;Motahareh Asgari,&nbsp;Chen-Guo Feng","doi":"10.1007/s00044-026-03576-9","DOIUrl":"10.1007/s00044-026-03576-9","url":null,"abstract":"<div><p>In the search for novel, highly effective antitumor agents, a series of novel 1,6-naphthyridine derivatives were designed, synthesized and evaluated for antiproliferative activity against five human cancer cell lines (HepG-2, MCF-7, NCI-H1650, U87MG and A549) using CCK-8 assay in vitro. Among them, compound (<i>R</i>)-<i>N</i>-(1-(3-(difluoromethyl)-2-fluorophenyl)ethyl)-8-(3-ethylphenyl)-7-methoxy-1,6-naphthyridin-4-amine (<b>16f</b>) exhibited promising broad-spectrum activity against all tested cell lines. It was particularly potent against U87MG cells, with IC₅₀ values of 3.28 ± 0.15 µM. The antitumor activity was significantly better than that of the positive control 5-fluorouracil. Preliminary mechanistic studies revealed that compound <b>16f</b> inhibited the clonogenic formation and migration of U87MG cells in a concentration-dependent manner, with migration inhibition also showing time dependence. Furthermore, <b>16f</b> induced apoptosis in a concentration-dependent manner by increasing the reactive oxygen species level within the cells. At a concentration of 4 µM, the apoptotic cell population increased from 3.92% (control) to 25.18%, representing a 6.4-fold increase. Nuclear damage observed via DAPI staining provided further evidence of its cytotoxic effects. The DAPI staining further confirmed the cytotoxic action of compound <b>16f</b>, showing clear morphological damage to the nuclei of U87MG cells. Collectively, these findings indicate that compound <b>16f</b> is a promising candidate for further development as a potent antitumor drug.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"35 6","pages":"1186 - 1200"},"PeriodicalIF":3.5,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148305994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring new quinoxaline, quinoline, and naphthalene carboxamides as HDAC-targeted anticancer agents: Cytotoxicity, enzymatic HDAC evaluation, and in silico studies","authors":"Jariya Jampahom,&nbsp;Jiratthakan Prathumchat,&nbsp;Siripit Pitchuanchom,&nbsp;Chadaporn Leerat,&nbsp;Narissara Namwan,&nbsp;Thanaset Senawong,&nbsp;Jantana Yahuafai,&nbsp;Kwanjai Kanokmedhakul,&nbsp;Chanokbhorn Phaosiri,&nbsp;Mongkol Nontakitticharoen","doi":"10.1007/s00044-026-03578-7","DOIUrl":"10.1007/s00044-026-03578-7","url":null,"abstract":"<div><p>Histone deacetylase inhibitors (HDACis) are important epigenetic anticancer agents, but new HDAC-targeted scaffolds are still needed to improve biological profiles. Herein, quinoxaline, quinoline, and naphthalene were selected as structurally related fused-aromatic cap groups within the HDAC inhibitor pharmacophore, allowing comparison of naphthalene and its aza-analogs in a unified carboxamide series. A new series of quinoxaline, quinoline, and naphthalene carboxamides was synthesized through amidation of amino acid methyl esters, followed by hydrolysis, hydrazinolysis, and hydroxamate formation. Their structures were confirmed by spectroscopic and mass spectrometric analyses. Cytotoxicity was evaluated against A549, HeLa, and MCF-7 cancer cells and non-cancerous Vero cells using the MTT assay. Most derivatives were weakly active; however, hydroxamic acids showed improved potency. Compound <b>10d</b> exhibited submicromolar cytotoxicity against A549, HeLa, and MCF-7 cells (IC₅₀ = 0.22, 0.13, and 0.21 µM, respectively), although it was also toxic to Vero cells. Compound <b>7d</b> showed selective cytotoxicity toward HeLa cells (IC₅₀ = 6.61 µM) with low Vero toxicity (IC₅₀ &gt; 100 µM). Enzymatic evaluation demonstrated that <b>10d</b> strongly inhibited HDAC activity in HeLa nuclear extract and showed potent HDAC2 inhibition, whereas <b>7d</b> showed weak total HDAC and low HDAC2 inhibition. Western blot analysis showed that <b>7d</b> increased Ac-H3 levels, suggesting possible epigenetic modulation. Apoptosis and cell-cycle analyses indicated strong late apoptosis and SubG1 accumulation by <b>10d</b>, whereas <b>7d</b> induced moderate late apopotosis and G2/M arrest. Molecular docking of <b>10d</b> with HDAC2 supported its binding within the catalytic pocket, and ADMET prediction suggested drug-like properties with potential liabilities requiring validation.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"35 6","pages":"1201 - 1221"},"PeriodicalIF":3.5,"publicationDate":"2026-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148305923","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Small Molecule Insulin Sensitisers: New Leads and Targets for Next-Generation Insulin Sensitising Strategies","authors":"Chong-Yew Lee","doi":"10.1007/s00044-026-03577-8","DOIUrl":"10.1007/s00044-026-03577-8","url":null,"abstract":"<div><p>Type 2 diabetes (T2D) is a major global health problem driven largely by insulin resistance, the impaired cellular response to insulin. Few current therapies directly address this underlying cause. Thiazolidinediones, potent peroxisome proliferator-activated receptor gamma (PPARγ) agonists, remain the only true small-molecule insulin sensitisers, but their clinical use is limited by adverse effects associated with non-selective activation of this target. Consequently, research has shifted toward alternative pathways that enhance insulin signalling without relying on PPARγ agonism. This review summarises advances from 2013 to 2025 in the development of novel small-molecule insulin sensitisers across diverse scaffolds and mechanisms. Structure-activity relationships, established and emerging molecular targets, and structural insights that inform rational drug design are highlighted. Selected leads were also evaluated using the BOILED-Egg model to assess oral drug-likeness and early “technology readiness.” Overall, this review aims to inspire medicinal chemists by presenting promising leads and strategies for the development of next-generation insulin-sensitising therapeutics.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"35 10","pages":"1905 - 1929"},"PeriodicalIF":3.5,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148434798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of a Potent Small Molecule Antagonist of GRPR for the Treatment of Pruritus","authors":"Mingzhou Zhou,&nbsp;Roland E Dolle,&nbsp;Amruta R Poreddy,&nbsp;Edmund C Hudson,&nbsp;Michelle A Schmidt,&nbsp;Margaret L Grapperhaus,&nbsp;Tom Gordon,&nbsp;Huaping Chen,&nbsp;Mike Prinsen,&nbsp;Xianyu Liu,&nbsp;Zhiyong E. Tao,&nbsp;Jinbin Xu,&nbsp;Ma Xenia G Ilagan,&nbsp;Zhou-Feng Chen","doi":"10.1007/s00044-026-03566-x","DOIUrl":"10.1007/s00044-026-03566-x","url":null,"abstract":"<div><p>Persistent pruritus (itch) affects the quality of life, and many itch syndromes remain untreatable. Previously, we identified the gastrin-releasing peptide receptor (GRPR) playing a critical role in mediating histamine-independent itch signaling. In this study, we aimed to identify small-molecule GRPR antagonists to treat histamine-independent itch. Starting with the known small-molecule GRPR antagonist PD 176,252, we conducted systematical structure-activity relationship studies. This effort led to the discovery of antagonists that exhibit up to an 11-fold increase in binding affinity compared to PD 176,252. Compound <b>45</b> (MP-4222), a GRPR antagonist with a four-fold increased binding affinity and equal selectivity over the neuromedin B receptor (NMBR), significantly inhibited itch behavior in the chloroquine (CQ)-induced acute itch mouse model. Additionally, we attempted to reconcile the discrepancy between our in vitro experimental data and the computational docking outcome using the recently reported GRPR-PD176252 cryo-EM structure. Our studies also suggested several potential modifications to improve potency, as well as identified functional groups that have the potential in radiolabeling for targeted GRPR imaging.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"35 6","pages":"1119 - 1140"},"PeriodicalIF":3.5,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00044-026-03566-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148306003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Design, synthesis, and activity study of heterocyclic derivatives as JAK inhibitors","authors":"Shukhrat Gaybullaev,&nbsp;MiaoMiao Shi,&nbsp;Deng Zang,&nbsp;Shan Yang,&nbsp;Jiale Yan,&nbsp;Sardor Shakarov,&nbsp;Yuldash Takhirov,&nbsp;Davron Turgunov,&nbsp;Liyin Jiang,&nbsp;Jiangyu Zhao,&nbsp;Khurshed Bozorov,&nbsp;Chao Niu","doi":"10.1007/s00044-026-03571-0","DOIUrl":"10.1007/s00044-026-03571-0","url":null,"abstract":"<div><p>The Janus kinase (JAK) family plays a central role in regulating inflammation and fibrosis through the JAK/STAT signaling pathway, making it an attractive therapeutic target for immune-mediated diseases. In the present study, structural modifications of the quinazoline core were systematically explored to identify potent JAK inhibitors. A CXCL10-based screening strategy identified compound <b>22a</b> as a promising lead, exhibiting strong inhibitory activity in HaCaT cells with an IC₅₀ value of 308 nM. Subsequent kinase assays demonstrated that compound <b>22a</b> exhibits higher inhibitory potency toward JAK1 (IC₅₀ = 37.86 nM) compared to JAK2 (IC₅₀ = 102.5 nM), JAK3 (IC₅₀ = 69.35 nM), and TYK2 (IC₅₀ = 2142 nM). Mechanistic studies revealed a dose-dependent suppression of STAT1 phosphorylation, confirming inhibition of the JAK1/2–STAT1 signaling pathway. In addition, molecular docking and molecular dynamics simulations were performed to elucidate and validate the binding mode of compound <b>22a</b> within the JAK1 active site. Collectively, these results indicate that the developed quinazoline derivatives represent promising leads for the further development of selective JAK1 inhibitors.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"35 6","pages":"1141 - 1160"},"PeriodicalIF":3.5,"publicationDate":"2026-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148305993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MRS2339, a cardiac P2X4 receptor nucleotide activator, improves systolic function in heart failure","authors":"Ronghua Yang,&nbsp;Chunxia Cronin,&nbsp;Khaled Qanud,&nbsp;T. Santhosh Kumar,&nbsp;Thomas Hintze,&nbsp;Fabio A. Recchia,&nbsp;Stanko S. Stojilkovic,&nbsp;Claudio Coddou,&nbsp;Kenneth A. Jacobson,&nbsp;Bruce T. Liang","doi":"10.1007/s00044-026-03575-w","DOIUrl":"10.1007/s00044-026-03575-w","url":null,"abstract":"<div><p>Growing evidence is highlighting purinergic receptors as therapeutic targets in cardiac diseases. MRS2339, a charged (N)-methanocarba derivative of 2-Cl-adenosine monophosphate, is efficacious in multiple animal models of systolic heart failure with reduced ejection fraction following infarction, pressure overload, calsequestrin overexpression, rapid pacing, and other injuries. In this study, we explored the beneficial mechanisms of this nucleotide analog in dogs with rapid pacing-induced systolic heart failure and in mice with postinfarct ischemic heart failure. In dogs, sustained infusion of the nucleotide analog increased stroke volume, cardiac output, arterial blood pressure, and arterial oxygen level without any vascular effects, suggesting direct cardiac effects of the drug. In the murine model, MRS2339 caused an increase in myocardial cyclic GMP level, a known cardioprotective second messenger in wild type mice, but no effects in P2X4 receptor knockout mice. Previous data showed that MRS2339 was able to elicit a current in adult mouse cardiomyocytes. The present data showed that MRS2339 could not stimulate a current through rat homomeric P2X4 receptors expressed in HEK293 cells. While the composition of endogenous cardiomyocyte P2X receptors is not known, P2X4 receptors in the heart appear necessary for MRS2339-induced cyclic GMP increase. Our findings support a novel cardiac P2X 4 receptor-mediated cyclic GMP enhancement by MRS2339 as a cellular mechanism of action in heart failure. Stimulating cardiac P2X receptors with increased cyclic GMP level to yield hemodynamic improvement is a potential new therapeutic target in heart failure.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"35 10","pages":"2045 - 2054"},"PeriodicalIF":3.5,"publicationDate":"2026-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s00044-026-03575-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148434664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Discovery of new bioactive secondary metabolites from the stem bark of oroxylum indicum: isolation, structural identification, antimicrobial and cytotoxicity assessment","authors":"Dixhya Rani,&nbsp;Meenakshi Sharma,&nbsp;Urvashi Dhiman,&nbsp;Tashi Palmo,&nbsp;Ashutosh Shahi,&nbsp;Kuljit Singh,&nbsp;Prasoon Gupta","doi":"10.1007/s00044-026-03572-z","DOIUrl":"10.1007/s00044-026-03572-z","url":null,"abstract":"<div><p>This study aimed to identify potent antimicrobial compounds from Ayurvedic plant <i>Oroxylum indicum</i>. Phytochemical examination of its stem bark led to the isolation of 29 chemical constituents, including five compounds for the first time from this genus: Chrysophanol (<b>12</b>), Ipriflavone (<b>15</b>), Pinoresinol diglucopyranoside (<b>22</b>), Quercetin 3-O-<i>β</i>-D-glucofuranoside (<b>28</b>), and 5-hydroxy-3,7,8,3′,4′-pentamethoxyflavone (<b>29</b>). Notably, compound <b>28</b> was a unique flavonoid bearing a <i>β</i>-D-glucofuranoside moiety, very rare in this class. Structural elucidation of the compounds (<b>1–29</b>) was achieved using 1D/2D NMR and HRESI-MS spectrometry. Antimicrobial susceptibility analysis identified two potent compounds (<b>28</b> and <b>29</b>) exhibiting MIC and MBC in the range of 0.09 µM to 1.5 µM and 0.7 µM to 6.25 µM against the tested bacterial pathogens, respectively. Further, bactericidal potential of the two identified hit were validated by time-kill kinetics studies. Cytotoxicity assessment in mammalian macrophage cell lines (RAW 264.7 and J774A.1) and hemolysis assays represented an acceptable cytocompatibility profile of these two molecules within the tested concentration range. These findings highlight molecules (<b>28</b> and <b>29</b>) as promising compounds for the development of novel antibacterial against Gram-positive and Gram-negative pathogens.</p><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"35 6","pages":"1161 - 1185"},"PeriodicalIF":3.5,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148305922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From lipophilicity windows to decision-grade antibacterial design: the next translational step for coumarin amphiphiles","authors":"M Vijayasimha,&nbsp;M Srikanth,&nbsp;S Hari Priya","doi":"10.1007/s00044-026-03574-x","DOIUrl":"10.1007/s00044-026-03574-x","url":null,"abstract":"","PeriodicalId":699,"journal":{"name":"Medicinal Chemistry Research","volume":"35 6","pages":"1003 - 1004"},"PeriodicalIF":3.5,"publicationDate":"2026-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148305947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}